Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
Successful proposals will secure fully funded postdoctoral research positions
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
The Karnataka Health Promotion Trust held a day-long session in New Delhi to address health care challenges
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
